End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.695 MYR | -1.42% | -2.80% | -1.42% |
03-12 | UMediC Group's Profit Slips in Fiscal Q2; Shares Rise 3% | MT |
03-11 | UMediC Group Berhad Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an enterprise value anticipated at 4.17 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.42% | 54.83M | - | ||
-4.84% | 182B | C+ | ||
+0.56% | 110B | C | ||
-3.35% | 68.11B | A | ||
+2.39% | 50.53B | B- | ||
+9.36% | 44.8B | B- | ||
+2.87% | 40.7B | B+ | ||
+24.51% | 32.3B | B | ||
+3.43% | 26.53B | A- | ||
+14.60% | 25.02B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- UMC Stock
- Ratings UMediC Group